1-15 of 15
Anna Truppel-Hartmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Clinical Trials & Observations
Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesús Berdeja, Sergio Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa McKiver, Paula Rodríguez-Otero
Journal: Blood
Blood (2024) 144 (23): 2389–2401.
https://doi.org/10.1182/blood.2024024582
Published: 2024
Includes: Supplemental data
Journal Articles

Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Barry Paul, Madhav V. Dhodapkar, Melissa Alsina, Jesús G. Berdeja, Shambavi Richard, Ravi Vij, Xavier Leleu, Daniel N. Egan, P. Leif Bergsagel, Ran Reshef, Saad Z. Usmani, Anna Truppel-Hartmann, Debashree Basudhar, Ethan G. Thompson, Fan Wu, Laurie Eliason, Soyun Park, Sinhan Tran, Maria Chaudhry, David S. Siegel, Krina K. Patel
Journal: Blood
Blood (2024) 144 (Supplement 1): 3388.
https://doi.org/10.1182/blood-2024-200829
Published: 2024
Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Madhav V. Dhodapkar, Melissa Alsina, Jesus G. Berdeja, Krina K. Patel, Shambavi Richard, Ravi Vij, Xavier Leleu, Daniel N. Egan, P. Leif Bergsagel, Ran Reshef, Saad Z Usmani, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Laurie Eliason, Xiaobo Zhong, Chiara Greggio, Sinhan Tran, Maria Chaudhry, Marlene J. Carrasco-Alfonso, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 2101.
https://doi.org/10.1182/blood-2023-173970
Published: 2023
Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Paula Rodríguez Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano Costa, Ravi Vij, Nizar J Bahlis, Philippe Moreau, Scott R. Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur S. Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesus G. Berdeja, Anna Truppel-Hartmann, Rashmi Bhatnagar, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-McKiver, Sergio A. Giralt
Journal: Blood
Blood (2023) 142 (Supplement 1): 1028.
https://doi.org/10.1182/blood-2023-178933
Published: 2023
Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3

Rachid Baz, Paula Rodriguez Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Ajay K. Nooka, Luciano Costa, Noopur S. Raje, Ingerid Weum Abrahamsen, Michel Delforge, Usama Gergis, Douglas W. Sborov, Sergio A. Giralt, Marc S. Raab, Tadao Ishida, Asya Varshavsky-Yanovsky, Taewoong Choi, Larry D. Anderson, Jr., Anna Truppel-Hartmann, Rashmi Bhatnagar, Fan Wu, Julia Piasecki, Jasper Felten, Andrea Caia, Mark Cook, Yi Lin
Journal: Blood
Blood (2023) 142 (Supplement 1): 4879.
https://doi.org/10.1182/blood-2023-174477
Published: 2023
Journal Articles

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Saad Usmani, Krina Patel, Parameswaran Hari, Jesus Berdeja, Melissa Alsina, Ravi Vij, Noopur Raje, Xavier Leleu, Madhav Dhodapkar, Ran Reshef, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Chiara Greggio, Linda Favre-Kontula, Lars Sternas, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 875–877.
https://doi.org/10.1182/blood-2022-162469
Published: 2022
Journal Articles

KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

Madhav Dhodapkar, Melissa Alsina, Jesus Berdeja, Krina Patel, Ravi Vij, Xavier Leleu, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Linda Favre-Kontula, Chiara Greggio, Lars Sternas, David Siegel
Journal: Blood
Blood (2022) 140 (Supplement 1): 7441–7443.
https://doi.org/10.1182/blood-2022-162615
Published: 2022
Journal Articles

CRC-403: A Phase 1/2 Study of bbT369, a Dual CD79a and CD20 Targeting CAR T Cell Drug Product with a Gene Edit, in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Frederick L. Locke, David B. Miklos, Michael Tees, Tina Bees, Aojun Li, Anna Truppel-Hartmann, Ian W. Flinn
Journal: Blood
Blood (2022) 140 (Supplement 1): 12716–12717.
https://doi.org/10.1182/blood-2022-162604
Published: 2022
Journal Articles

Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma from the KarMMa Study

Paula Rodriguez-Otero, Jesús F. San-Miguel, Larry D. Anderson, Jr., Sagar Lonial, Anna Truppel-Hartmann, Jill Sanford, Everton Rowe, Timothy B. Campbell, Nikhil C. Munshi
Journal: Blood
Blood (2021) 138 (Supplement 1): 2743.
https://doi.org/10.1182/blood-2021-147990
Published: 2021
Journal Articles

Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma

Noopur S. Raje, Nina Shah, Sundar Jagannath, Jonathan L. Kaufman, David S. Siegel, Nikhil C. Munshi, Jacalyn Rosenblatt, Yi Lin, Andrzej Jakubowiak, Alison Timm, Ashish Yeri, Nathan Martin, Timothy B. Campbell, Olivia Finney, Anna Truppel-Hartmann, Fabio Petrocca, Jesús G. Berdeja, Melissa Alsina
Journal: Blood
Blood (2021) 138 (Supplement 1): 548.
https://doi.org/10.1182/blood-2021-146518
Published: 2021
Journal Articles

Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma

Ankit Kansagra, MD, Yi Lin, MD PhD, Jesus G. Berdeja, MD, Nina Shah, MD, Albert Oriol, MD, Ibrahim Yakoub-Agha, Hermann Einsele, MD, Alessandro Rambaldi, MD, Anna Truppel-Hartmann, MD, Everton Rowe, PhD, Julie Wang, PharmD, PhD, Amit Agarwal, MD PhD, Timothy B. Campbell, MD PhD, Sagar Lonial, MD FACP
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-134383
Published: 2020
Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis

Jesus G. Berdeja, MD, Noopur S. Raje, MD, David S. Siegel, MD PhD, Yi Lin, MD PhD, Larry D. Anderson, Jr., MD PhD, Paula Rodriguez-Otero, MD PhD, Salomon Manier, MD PhD, Hermann Einsele, MD, Michele Cavo, Anna Truppel-Hartmann, MD, Everton Rowe, PhD, Jill Sanford, MS, Julie Wang, PharmD, PhD, Timothy B. Campbell, MD PhD, Sundar Jagannath, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-134322
Published: 2020
Journal Articles

KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma

Saad Z. Usmani, MDMBBS,MBA, Jesus G. Berdeja, MD, Anna Truppel-Hartmann, MD, Marie-Laure Casadebaig, Honeylet Wortman-Vayn, Suresh G. Shelat, PhD, Steven Novick, MDPhD, Nina Shah, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-139009
Published: 2020
Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study

Noopur S. Raje, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Sagar Lonial, MD FACP, Nikhil C. Munshi, MD, Philippe Moreau, MD, Hartmut Goldschmidt, MD, Michele Cavo, Anna Truppel-Hartmann, MD, Everton Rowe, PhD, Liping Huang, PhD, Amit Agarwal, MD PhD, Julie Wang, PharmD, PhD, Timothy B. Campbell, MD PhD, Jesus F. San-Miguel, MD PhD, Donna E. Reece, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-134319
Published: 2020
Journal Articles

Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Francesc Bosch, MD PhD, Thomas Illmer, MD, Mehmet Turgut, MD PhD, Agostino Cortelezzi, MD, Susan F. Lasserre, MSc, Anna Truppel-Hartmann, MD, Veronique Leblond, MD PhD, Robin Foà, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2014) 124 (21): 3345.
https://doi.org/10.1182/blood.V124.21.3345.3345
Published: 2014